Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2017

2017-08-14
Price :
Published : Aug-2017
No. of Pages : 92

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2017

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2017″, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q2 2017 with 1,110 deals worth USD91.3 billion, as compared 1,224 worth USD163.8 billion in Q2 2016. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q2 2017, when compared to 1,185 deals worth USD95.9 billion in Q1 2017. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD725.3m in Q2 2017, as compared USD1.1 billion in Q2 2016. On a quarter-on-quarter basis, the upfront payments reported a marginal increase in Q2 2017, when compared to USD723.6m in Q1 2017. Deals in oncology therapeutics market registered a decrease with 374 deals in Q2 2017, compared to 434 deals in Q1 2017. North America reported a decrease in the number of deals from 798 in Q1 2017 to 696 in Q2 2017.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

Hemorrhagic Shock Global Clinical Trials Review, H2, 2017

Hemorrhagic Shock Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhagic Shock Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhagic Shock clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhagic Shock. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Hepatitis E Global Clinical Trials Review, H2, 2017

Hepatitis E Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatitis E Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis E clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis E. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hemorrhoids Global Clinical Trials Review, H2, 2017

Hemorrhoids Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhoids Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhoids clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhoids. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatobiliary Disease Global Clinical Trials Review, H2, 2017" provides an overview of Hepatobiliary Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatobiliary Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Hemostasis Global Clinical Trials Review, H2, 2017

Hemostasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemostasis Global Clinical Trials Review, H2, 2017" provides an overview of Hemostasis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemostasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Hemochromatosis Global Clinical Trials Review, H2, 2017

Hemochromatosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemochromatosis Global Clinical Trials Review, H2, 2017" provides an overview of Hemochromatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemochromatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Encephalopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Encephalopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma e......
$2500

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hepatorenal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatorenal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500